Comparative Evaluation of Two Different Doses of Fentanyl with Standard Dose of Propofol and Midazolam to facilitate Laryngeal Mask Airway Insertion in Children: A Study of 60 cases by Ganessan, R
COMPARATIVE EVALUATION OF TWO DIFFERENT 
DOSES OF FENTANYL WITH STANDARD DOSE OF 
PROPOFOL AND MIDAZOLAM TO FACILITATE 
LARYNGEAL MASK AIRWAY INSERTION IN CHILDREN
A study of 60 cases 
DISSERTATION SUBMITTED FOR THE DEGREE OF 
DOCTOR OF MEDICINE 
ANAESTHESIOLOGY 
(BRANCH – X)
MARCH 2007
THE TAMILNADU DR.M.G.R. MEDICAL UNIVERSITY 
CHENNAI 
DEPARTMENT OF ANAESTHESIOLOGY
MADURAI MEDICAL COLLEGE
MADURAI
CERTIFICATE
This is to certify that the dissertation entitled “COMPARATIVE
 
EVALUATION OF TWO DIFFERENT DOSES OF FENTANYL 
WITH STANDARD DOSE OF PROPOFOL AND MIDAZOLAM
 
TO FACILITATE LARYNGEAL MASK AIRWAY INSERTION IN 
CHILDREN” is a bonafide record work done by DR.R.GANESSAN,
 in the Department of Anaesthesiology, Government Rajaji Hospital,
 
       Madurai Medical College, Madurai. 
Professor and Head, 
Department of Anaesthesiology, 
Government Rajaji Hospital, 
                                                             Madurai Medical College, Madurai. 
ACKNOWLEDGEMENT
             At the outset, I express my gratitude to Prof. DR.I.CHANDRASEKARAN MD.,  
DA.,  Chief  and Head of  Department  of  Anaesthesiology,  Madurai  Medical  College,  
Madurai for his constant motivation, valuable guidance and support to this study.
 My  special  thanks  to  PROF.  R.S.P.MEENAKSHI  SUNDARAM,  MD.,DA., 
Additional Professor of Anaesthesiology, for his encouragement and guidance in doing 
this project work.. 
I am thankful to DR.. THIRUNAVUKKARASU, MD., DA., Additional Professor 
of Anaesthesiology for his constant support and guidance in doing this study.  
My sincere thanks to  DR S.SUBBIAH  MD., DA., .DCH, M.N.AM.S.,  Former 
Professor of Anaesthesiology for his encouragement and critical suggestions. 
I  wish  to  thank  our  DEAN;  Dr.  S.M.  SIVAKUMAR M.S. Madurai  Medical  
College, Madurai for permitting me to carry out this clinical study in our hospital. 
I  am  greatly  indebted  to  my  Assistant  Professors  DR.R.SHANMUGAM 
M.D.DCH., and DR.T.NIRMALA DEVI .MD.D.A, who provided all the assistance in 
doing my project work..
I  am greatly  thankful  to  all  of  my  Assistant  Professors for  their  support  and 
guidance rendered towards this thesis.
I thank all the post graduates who helped me in doing this study.
I thank all my patients of Government Rajaji Hospital, Madurai, without whom 
this study would not have been possible. I also pray for their speedy recovery.  
 
DECLARATION
I, Dr. R.GANESSAN, solemnly declare that the dissertation titled 
“COMPARATIVE EVALUATION OF TWO DIFFERENT DOSES 
OF FENTANYL WITH STANDARD DOSE OF PROPOFOL AND
 MIDAZOLAM TO FACILITATE LARYNGEAL MASK AIRWAY
 INSERTION IN CHILDREN” has been prepared by me. 
This is submitted to The Tamilnadu Dr.M.G.R.Medical University, Chennai, in 
partial fulfillment of the regulations for the award of MD degree Branch – X 
[Anaesthesiology].
 Date: 
Madurai. Dr. R.GANESSAN
Sl. No. Titles Page no.
1 Introduction 1
2 Aim of the study 3
3 Review of literature 4
4 Anatomy 9
5
The Laryngeal Mask Airway (LMA)
History and Concepts 16
6
Pharmacology
Propofol
Fentanyl
Midazolam
29
36
43
7 Materials and methods 52
8 Observation and results 57
9 Discussion 61
10 Summary and conclusion
Bibliography
Proforma
Master chart
69
72
                                            INTRODUCTION
Laryngeal mask airway (LMA) was developed in 1981 by Dr.Archie Brain   in the 
United Kingdom.It represents a novel concept in airway management that allows air 
exchange through a specially designed mask that fits in the hypopharynx and faces the 
laryngeal inlet, creating an end –to-end seal .Pediatric –sized LMAs are simply scaled –
down versions of the adult variety, even though newborns and infants display significant 
differences in airway anatomy from older children and adults.
The LMA has established role in routine pediatric anaesthesia, management of difficult 
pediatric airway and diagnostic airway procedures. The insertion of LMA stimulates the 
hard and soft palate, posterior pharyngeal wall and hypo pharynx. This requires adequate 
anaesthesia, but the depth required is less compared to endotracheal intubation. The 
main advantages of LMA over endotracheal intubation are avoidance of muscle relaxant 
and minimal cardiovascular response.
For successful LMA insertion good induction agents like propofol, potent narcotics like 
fentanyl, alfentanil and anxiolytics like midazolam are necessary. The purpose of this 
prospective randomized study was to assess the LMA insertion conditions and 
hemodynamic changes comparing different doses of fentanyl with standard dose of 
propofol and midazolam.
 AIM OF THE STUDY
To assess the ease of insertion of laryngeal mask airway in children comparing the use 
of  two  different  doses  of  fentanyl  (1mcg/kg  &  2mcg  /kg)  with  standard  doses  of 
(propofol  2.5  mg/kg  and  midazolam  0.05mg  /  kg).  To  compare  the  hemodynamic 
parameters in both the groups.
                             REVIEW OF LITERATURE
Efrat R, Kadari A, Katz S.1994 (Journal of pediatric Anaesthesia)  reported their 
experience with LMA on 120 consecutively treated children who underwent elective 
inguinal herniorrhaphy or orchidopexy Anesthesia was induced and maintained with 
halothane, nitrous oxide oxygen . Patients were allowed to breath spontaneously until 
anesthesia was deep enough (average, 6.3 minutes; range, 2 to 15 minutes). The 
appropriate-size LMA was inserted and inflated and patients were divided into three 
groups. Group I weighed 2.6 to 6 kg and received LMA size no. 1. Group II weighed 6 
to 30 kg and received LMA size no. 2. Group III weighed more than 30 kg and received 
LMA size no. 3. The LMA was easily inserted in 115 patients (95.8%)--on the first 
attempt in 100, and on the second attempt in 15. In five patients, LMA was successfully 
inserted on the third attempt. The ease of insertion was not significantly different 
between the groups. 
O'Neill, Barbara, MD; Templeton, Josephine J., MD; Caramico, Lisa, MD; 
Schreiner, Mark S., MD.et al 1993 did a study and concluded that use of the laryngeal 
mask airway (LMA) permits the maintenance of a patent airway with successful 
insertion rates of the LMA on the first attempt varying between 67%–92% in children. 
Insertion of the LMA partially inflated required significantly less time (16 vs. 23 s), and 
was associated with a higher success rate on first attempts (85.5% vs. 96.7%). 
                                                                                                                                                          Gursoy, 
Feray, MD, Algren, John T., MD et al studied the safety of size 2 LMA in children 
undergoing elective surgery. They concluded that the size 2 LMA provides an effective 
airway for PPV. Mild gastric distention often occurs. The risk of clinically significant 
gastric distention appears to be small, but it warrants close monitoring. We conclude that 
with certain precautions described in the text, the size 2 LMA provides a relatively safe 
airway for PPV in children.
M. Kodaka, Y. Okamoto, F. Handa, J. Kawasaki and H. Miyao et al did a study to 
determine the effective concentration for 50% of the attempts to secure laryngeal mask 
insertion (predicted EC50LMA) of propofol using a target-controlled infusion 
(DiprifusorTM) .Predicted EC50LMA of the control, fentanyl 0.5, 1 and 2 µg kg–1 
groups were 3.25 (0.20), 2.06 (0.55), 1.69 (0.38) and 1.50 (0.54) µg ml–1 respectively; 
those of all fentanyl groups were significantly lower than that of control. A fentanyl 
dose of 0.5 µg kg–1 is sufficient to decrease predicted EC50LMA with minimum 
respiratory depression and without a high BIS value.
Martlew et al (BJA 1996) studied the effective doses of propofol for 
insertion of LMA in 50 unpremedicated children and in 60 children 
premedicated with midazolam (0.5 mg/kg 30-60 minutes before 
anaesthesia).Propofol requirements in premedicated children were reduced by 
one-third. The doses required for satisfactory LMA insertion in 50% and 90% 
of unpremedicated children were3.8 mg/kg and 5.4 mg/kg respectively; those 
for premedicated children were 2.6 mg/kg and 3.6 mg/kg respectively.
Miriam Harnett,Brian Kinirons  et al did a study to compare the incidence of airway 
complications in children less than one year of age whose airways were maintained 
during anesthesia with either a laryngeal mask airway (LMA) or a facemask and oral 
airway (FM-OA).Airway complications occurred preoperatively in 15 of 27 infants in 
the LMA group and in 5 of 22 infants in the FM-OA group 
                                                                                                             
Brimacombe, J. et al in 1996 studied the Safety and efficacy of the laryngeal mask 
airway in 1400 children. Placement was successful in 90% (1258/1400) at the first 
attempt, 8% (112/1400) at the second attempt and 2% (29/1400) required an alternative 
technique. They concluded that the laryngeal mask provides a safe and effective form of 
airway management for infants and children in the hands of supervised anaesthesia 
trainees both for spontaneous and controlled ventilation using either isoflurane or total 
intravenous anaesthesia. 
Pankaj Kundra MD et al conducted a study in 62 ASA 1 and 2 children who were 
randomly allocated for the evaluation of LMA insertion by the midline approach with 
the cuff completely deflated or laterally with the cuff partially inflated. Propofol was 
used as the sole induction agent in all children. Ease of insertion, position of the LMA 
with fibreoptic laryngoscope and incidence of stomach insufflation were assessed.
They concluded that fewer attempts and a significant reduction in the time for insertion 
was noted in group with lateral insertion partially inflated technique compared with 
group midline classical technique. 
BRIMACOMBE J, 1995 performed a randomized prospective study trial comparing 
the LMA with other forms of airway management to determine if the LMA offered any 
advantages over the tracheal tube. The LMA has thirteen advantages over the tracheal 
tube. It has two disadvantages over the tracheal tube.
HICKEY, et al 1990 recovered the cardiovascular changes during laryngeal mask 
airway insertion and found that this was comparable to that of insertion of Guedel’s 
airway.
Mason DG, Bingham RM. et al used  LMA in 200 children during a variety 
of surgical procedures. Some problem with the use of the device was 
encountered in 47 cases (23%), but in only five cases (2.5%) were the 
problems serious enough to warrant abandonment of its use. A clear airway 
was ultimately achieved in 191 children. The mask was used in 16 children 
with known airway problems. It is concluded that the size 2 laryngeal mask 
airway can be successfully used within the weight range 6-30 kg.
ANATOMY
ORAL CAVITY
The oral cavity or buccal cavity consists of a narrow vestibule outside the teeth 
and an inner, large oral cavity proper.  The oral cavity proper is bounded in front and 
laterally  by  the  alveolar  arches,  teeth  and  gums;  behind  it  communicates  with  the 
pharynx at the oropharyngeal isthmus.  Its roof is formed by the hard and soft palates. 
Its floor is mainly formed by the anterior region of the tongue and the remainder by the 
mucosa lying on the mylohyoid anteriorly and laterally between the base of the tongue 
and the internal surface of the mandible on to which it is reflected.
PALATE
The palate or the oral roof is divisible into two regions, the hard palate and soft 
palate.
HARD PALATE
It is formed by the palatine process of the maxillae and the horizontal plates of the 
palatine bones.  It is bounded in front and at the sides by the superior and inferior arches 
of the alveolar processes and gums and is continuous posteriorly with the soft palate.  It 
is covered with stratified squamous epithelium.
SOFT PALATE
It is a mobile flap suspended from the posterior borders of the hard palate, sloping 
down and backwards between the oral and nasal parts of the pharynx.  It is a thick fold 
of mucosa enclosing an aponeurosis, muscular tissue vessels, nerves, lymphoid tissue 
and mucous glands.  In its usual position, released and pendant, its anterior surface is 
concave with a median raphe, its posterior surface is  convex and continues with the 
nasal floor, its anterosuperior border is attached to the hard palate’s posterior margin, its 
sides blend with the pharyngeal wall and its inferior border is free hanging between the 
mouth and pharynx.  A median conical process, the uvula projects downwards from its 
posterior border.
The arches of the palate curves as two folds of mucosa containing muscle, which 
descends laterally from each side of the soft palate.  The anterior palatal arch contains 
palatoglossus muscle which descends to the side of the tongue at the junction of its oral 
and pharyngeal parts forming lateral limits of the oropharyngeal isthmus.  The posterior 
palatopharyngeal arch contains the palatopharyngeus muscle and descends on the lateral 
wall of the pharynx.
Nerve Supply:
The  sensory  nerve  issue  from  the  greater,  lesser  palatine  and  nasopalatine 
branches  of  the  maxillary  nerve  and  also  the  glossopharyngeal  nerve  posteriorly. 
Parasympathetic post ganglionic secretomotor fibres arising from the facial nerve supply 
the palatine mucus glands via the pterygopalatine ganglion.  It is also possible that some 
parasympathetic  fibres  pass  to  the  posterior  parts  of  the  soft  palate  from  the 
glossopharyngeal nerve perhaps synapsing in the otic ganglion.  Sympathetic fibres run 
from the carotid plexus along the arterial branches supplying this region.
All the palatine muscles are supplied by nerve fibres which leave the medulla in 
the cranial part of accessory nerve and reach the pharyngeal plexus via the vagus and 
possibly glossopharyngeal nerve except for the tensor vali palatine which is innervated 
by the mandibular nerve.
Pharynx:
It is situated behind the nasal  cavities, mouth and larynx, a musculomembranous 
tube 12  - 14 cm long, extending from the cranial base to the level of the sixth cervical 
vertebra  and  the  lower  border  of  cricoid  cartilage,  where  it  continuous  with  the 
esophagus.
Oropharynx
Oropharynx extends from the soft palate to the upper border of the epiglottis.  It opens 
into  the  mouth  through  the  oropharyngeal  isthmus.   Its  lateral  wall  consists  of  the 
palatopharyngeal arch and palatine tonsils.  Posteriorly it is in level with the body of 
second and upper part of the third cervical vertebrae.
Laryngopharynx
Laryngeal part of the pharynx extends from the superior border of epiglottis to the 
inferior border of cricoid cartilage where it becomes continuous with the esophagus.  In 
its incomplete anterior wall is the laryngeal inlet and below this is the posterior surface 
of the arytenoids and cricoid cartilage.  A small pyriform fossa on each side of the inlet 
is bounded medially by the aryepiglottic fold and laterally by the thyroid cartilage and 
thyrohyoid membrane.
Muscles:
Pharynx consists of three constrictor muscles superior, middle and inferior and a 
trio of muscles descending from styloid processes. It also contains cartilaginous tissue of 
pharyngotympanic  tube  and  muscles  of  the  soft  palate  like  stylopharyngeus, 
salpingopharyngeus,  and  palatopharyngeus.   All  the  above  mentioned  muscles  pass 
obliquely into the muscular wall.
Nerve Supply of the pharynx
Innervation is mainly from the pharyngeal plexus.  The principal  motor element 
is  the cranial part  of the accessory nerve, which through vagal branches supplies all 
pharyngeal and palatine muscles except the stylopharyngeus (glossopharyngeal nerve) 
and the  tensor  vali  tympani  (mandibular  nerve).   The  main sensory nerves are  the 
glossopharyngeal  nerve  and  vagus.   The  mucosa  of  nasopharynx  is  supplied  by 
maxillary nerve via the pterygopalatine ganglion.  The mucosa of the soft palate and the 
tonsil is supplied by the lesser palatine and glossopharyngeal nerve..
Post ganglionic sympathetic fibres reach the pharyngeal plexus from the superior 
cervical ganglion.  Parasympathetic supply issue from the medulla oblongata chiefly in 
the  glossopharyngeal  nerve.   The  vagus  carries  branchial  efferent  fibres  for  the 
pharyngeal striated musculature.
                             
   
HISTORY AND CONCEPTS
Dr. A. I J . BRAIN viewed the mechanical aspects of endotracheal intubation in which 
an artificial tube is inserted into the trachea, the natural tube, and a cuff being inflated to 
form a gas tight seal. He found that in engineering terms, the solution to this problem of 
forming  a  gas  tight  junction  between  two  tubes  is  rather  unsatisfactory,  since  it 
necessarily involves a degree of constriction at the point of junction unless the outer tube 
(trachea) itself is expanded to compensate. He felt ideally, it is desirable that both tubes 
are  of  the same internal  diameter  at  the point  of  their  junction,  since  this  has  clear 
advantages  in  terms  of  gas  flow  without  constriction  in  the  tubes.  This  involves 
connecting them end to end since the option of expanding the anatomical tube (trachea) 
is not possible.
Based on the above concepts of the airway, Dr. BRAIN tried to produce an airway, 
which directly faced the larynx yet it should provide a gas-tight seal. He examined the 
postmortem specimens of adult male and female larynx to assess how such a joint might 
be achieved. He examined the shape of the pharynx by making plaster of paris casts 
from these  specimens  (cadavers).  He  noted  that  an  air-tight  seal  could  be  effected 
against  the  perimeter  of  the  larynx  posteriorly  by  an  elliptical  cuff  inflated  in  the 
hypopharynx. This observation led to the concept of laryngeal mask airway
STRUCTURAL CHARACTERISTICS.
The primary structural component of the LMA is medical-grade silicone rubber 
containing no latex. The LMA consists of a large –bore tubular structure (airway tube) 
housed proximally with a 15 mm airway adapter, whereas the distal end is  attached at a 
shallow angle to a flattened oval shaped mask. This mask is bordered by an inflatable 
cuff attached to  a pilot tubing containing a valve and  indicator balloon. The opening of 
the airway tube into the mask is confined by two aperture bars that restrict the epiglottis 
from herniating into the lumen of the airway tube.
When in proper position, the body of the mask of the LMA is designed to lie in the 
hypopharynx, with the distal tip of the mask just above the upper esophageal sphincter, 
the proximal aspect of the mask juxtaposed with the base of the tongue and the sides of 
the mask facing the pyriform fossae.As the cuff is inflated, a low pressure seal is created 
around the periphery of the laryngeal inlet.
DIFFERENT LMA SIZES AVAILABLE AND THEIR SPECIFICATIONS
SIZE ID
(mm)
OD
(mm)
LENGTH
(cm)
CUFF 
VOLUME-
PATIENT SIZE
up to( in ml)
1 5.25 8.2 8.8 4
Neonates/infants 
upto 5 Kg
1.5 6.1 9.6 10 7 Infants 5-10Kg
2 7 11 11 10 Children 10-20 
Kg
2.5 8.4 13 12.5 14 Children 
20-30Kg
3 10 15 16 20 Children, small 
adults >30-50
4 10 15 16 30 Adults 50-70
5 11.5 16.5 18 40 adults 50-70Kg
6 11.5 16.5 18 50
Large adults 
>100 Kg
MODIFIED VERSIONS
LMA UNIQUE - This is a disposable LMA for single use made from PVC used for 
emergency airway management.
LMA SAFEGAURD - Has different color coding of pilot balloons for use in various 
departments in hospitals
Dark blue – theaters
Pale blue – day care surgeries
Green – CPR
Yellow non metallic – MRI room
FLEXIBLE LMA – has flexible wire reinforced tube allowing it to be positioned away 
from the surgical field without occluding the lumen.
INTUBATING LMA- specially designed to aid endotracheal intubation with an 
appropriate tube without any manipulation of head and neck during placements.
LMA PRO-SEAL – specially designed for use with positive pressure ventilation with 
and without muscle relaxant at high airway pressures. It however doesn’t completely 
protect the airway from aspiration.
CLEANING
LMA should be cleaned and sterilized before each use. It should be washed immediately 
after removal, immersed in 8.4% sodium bicarbonate to dissolve secretions before 
cleaning with warm water. It should be autoclaved with a minimum temperature of 134 
deg centigrade. Cuff will be damaged if not completely deflated before autoclaving.
INSTRUCTIONS BEFORE USE
The interior of the tube should be free from obstruction or foreign particles. Exterior 
should be free from cracks, abrasions. When the tube is flexed at 180 degrees kinking 
should not occur. The epiglottic bars should be probed gently so as to make certain that 
they are not damaged. The valve should be tested and replaced if the cuff reinflates 
spontaneously after being completely deflated.
LARYNGEAL MASK AIRWAY SELECTION AND PREPARATION
Prior to inserting the LMA, it must be cleaned according to the manufacturer’s 
guideline and the cuff examined (both in the fully inflated and fully deflated form) for 
its integrity and symmetry.  The LMA cuff must then be evenly deflated to create a 
mask  that  is  cup  shaped,  with  the  tapered  rim of  the  cuff  pointing  away  from the 
aperture.  This is important in helping steer the tip of the mask posterior to the epiglottis 
during its descent into the hypopharynx. The posterior surface of the mask should be 
coated with a water-soluble lubricant just prior to insertion so that it easily glides against 
the palate and posterior pharynx.
TECHNIQUES OF LMA INSERTION
The standard method is a midline approach with the cuff fully deflated and the mask 
aperture facing forward. The dominant hand is used to hold the LMA like a pen at the 
distal end of the insertion tube, with the index finger wedged in the groove created by 
the attachment between the insertion tube and the mask.The LMA is inserted midline 
into the mouth and the distal end of the mask is juxtaposed against the proximal hard 
palate so that the tip of the mask is angled cadual.The LMA is then advanced while the 
Index finger applies pressure in a mainly cephalad and slightly posterior fashion. The 
index  finger  follows  the  LMA  along  the  palatopharyngeal  arch  into  the 
hypopharynx.The opposite hand is used to secure the proximal end of the LMA as the 
index dinger is removed and the LMA is advanced until resistance is felt. The cuff is 
gently inflated allowing the mask to conform the shape of hypopharynx.
An alternative technique is the “Guedel” method. It involves placing the LMA into the 
mouth with the device turned 180 degrees from the standard technique so that the mask 
opening is facing the hard palate.As the mask is advanced into the hypopharynx, it is 
turned 180 degree. The Guedel method may be more likely to result in damage to the 
soft tissues in the oropharynx.
Other  method  is  the  partial  inflation  method to  facilitate  insertion  to  increase  the 
success rate of insertion (96.7 vs. 85.5%) and a shorter time for insertion (16 vs. 23 sec).
In the “thumb” technique the LMA is inserted into the mouth in a manner similar to 
the standard technique except that it is the thumb (instead of the index finger) that is 
wedged in the groove between the mask and the insertion tube and used to apply the 
driving force to push the LMA against the hard palate and into the oropharynx.
Other  method  uses  a  slight  lateral  rotation  of  the  LMA during  insertion  to  help 
negotiate the angle between the palate and the posterior pharynx.. Lubrication should be 
applied to the posterior surface of the cuff just before insertion taking care to avoid the 
lubricant getting on the anterior surface. 
INDICATIONS;
1. The LMA is indicated for routine securing of a patient airway during general 
anaesthesia as long as there is no contraindication to the use of   face mask.
2. The LMA is especially useful when tracheal intubation is not necessary or is 
undesirable (e.g. Patients undergoing laser treatment of facial port wine stains, as 
well as infants or children with tracheal stenosis, bronchopulmonary dysplasia and 
so forth).
3. It has applications for patients with difficult airways both in facilitating tracheal 
intubation and in accomplishing lung ventilation where it is impossible to do so 
by face mask..
4. It provides a suitable airway in patients with limited neck mobility.
5. It can be used for diagnostic laryngoscopy and bronchoscopy.
6. It is used in routine elective cases where tracheal intubation is not required or is 
required only because the surgery interferes with maintenance of the airway with 
a face mask.
7. It is useful in cases where maintenance of airway with a face mask is difficult 
such as edentulous patients, facial injuries or burns.
8. It is useful in elective eye surgeries since changes in intraocular pressure are 
smaller when compared to intubation.
9. The LMA is now being used in anaesthesia for MRI.
10. In patients undergoing radiotherapy under general anaesthesia, the use of LMA 
can avoid repeated tracheal intubation.
CONTRAINDICATIONS AND LIMITATIONS;
The LMA does not protect the trachea from regurgitation and aspiration and is not meant 
to replace an endotracheal tube when the latter is indicated.Full stomach, nonfasted 
patients, those with morbid obesity, recent trauma, gastroesophageal reflux, intestinal 
obstruction are all contraindications.Patients with reduced pulmonary compliance where 
high positive pressure (>25-30 cm H2O ) may be needed for ventilation is also a contra 
indication.Oral tumors, periglottic pathologies ,circumstances where the airway cannot 
be readily accessed .i.e. head draped and away from the anesthetist ,prone position 
represent a relative contraindication to its use.
PATIENT SELECTION AND PREPARATION;
Patients who are at risk of pulmonary aspiration or those with reduced lung compliance 
are excluded. Children of ASA physical status 1 &2 with no congenital or acquired 
airway malformations (without airway difficulty) are included in the study.
ADVANTAGES;
1. It allows rapid establishment of an airway in the pediatric patient without the 
necessity for muscle relaxation.
2. Skill of placement is easily learned.
3. Less anaesthetic depth is required.
4. It provides a more suitable and trouble – free – airway than the face mask.
5. Unlike the face mask the LMA frees the hands of the anaesthesiologist and does 
not require jaw support.
6. The LMA unlike face mask or endotracheal tube does not have to be optimally 
positioned for a suitable airway to be maintained.
7. It does not injure the vocal cords or the trachea and thus does not cause the 
hemodynamic response associated with intubation.
8. The intracranial and intraocular pressure changes are less during LMA insertion 
than during intubation.
9. It does not stimulate bronchospasm in susceptible patients.
10.Incidence of sore throat and subsequent respiratory tract infection is less when 
compared to tracheal tube.
11.Smooth emergence from anaesthesia.
12. Insertion of LMA does not cause significant bacteremia when compared to nasal 
intubation.
13. Because of the larger lumen size of the LMA, there is less increase in airway 
resistance in spontaneous respiration.
DISADVANTAGES;
1. Optimal air leak around the LMA must be limited (average 20-25 cm H2O) to 
avoid insufflation of the stomach. This restricts the amount of positive pressure 
that can be applied to the lungs.
2. The LMA is not useful in stenting or maintaining patency in tracheomalacia or a 
trachea that is compressed or is obstructed at or below the laryngeal inlet.
3. While using an LMA it may be more difficult to differentiate laryngospasm or 
bronchospasm from incorrect placement and more difficult to apply positive 
pressure to break laryngospasm.
4. There is increased risk of gastric aspiration, especially in obese patients.
5. LMA is unsafe in prone and jack knife position.
COMPLICATIONS;
1. Accidental dislodgement can occur.
2. Airway obstruction and airway injury.
3. Nerve injury—Palsies of hypoglossal, recurrent laryngeal and lingual nerves have 
been reported after use of LMA.
                               
                                                PHARMACOLOGY
                                                 PROPOFOL
Propofol  is 2, 6, di-isopropylphenol which was introduced into clinical practice in 
1977  as  1%  solution  solubilized  in  cremophor  EL.  Due  to  anaphylactoid  reactions 
associated with cremophor EL the drug was reformulated in an emulsion.
Physiochemical Properties
Propofol is alkyl phenol oil at room temperature, insoluble in aqueous solution but 
highly lipid soluble.  The present formulation consists of 1% Propofol, 10% soyabean 
oil, 2.25% glycerol and 1.2% egg phosphate.  It has PH of 7.0 and appears viscous, 
milky white substance pKa is 11.
Pharmacokinetics
The  intravenous  administration  of  single  bolus  induction  dose  of  Propofol  is 
followed by rapid decrease  in  the  blood level  as  a  result  of  both  redistribution  and 
elimination.  Propofol is 98% protein bound.  The half- life is 2.5 min and   phase half-
life is 1 – 3 hrs.  The volume of distribution for propofol at steady state is 3.5 -4.5 lit/kg. 
Propofol has very high clearance 30-60 ml/kg/min.  Propofol is rapidly metabolized in 
liver by conjugation to glucuronide and sulfate to produce water-soluble compounds 
which are excreted by kidneys.
Pharmacodynamics
CNS: Propofol in adequate dosage causes rapid onset of unconsciousness in 11-15 
seconds  by  enhancing  the  GABA  activated  chloride  channel.   Propofol  is  not 
antanalgesic.  The excitatory phenomenon such as involuntary movements may be seen 
with induction.  It produces dose related depression in EEG.  The effect of propofol on 
epileptogenic EEG activity is controversial.  Propofol reduces the cerebral blood flow 
and CMRO2.Propofol  decreases  ICP in  patients  with  either  normal  or  elevated  ICP. 
Intraocular  pressure  is  also  reduced  with  Propofol.   Patients  on  awakening  from 
anaesthesia appear to have less post operative sedation, are alert and show no – hang 
over.  Psychomotor  function  following  propofol  anaesthesia  is  good  and  recovery  is 
rapid.  Propofol produces low incidence of nausea, vomiting and headache.
Respiratory system
Propofol produces dose dependant respiratory depression.  There is marked initial 
reduction  in  tidal  volume  following  a  normal  induction  dose  of  propofol  often 
amounting to a period of apnea varying from 30-60sec.  The onset of apnea is preceded 
by marked tidal volume reduction and tachypnoea.  Propofol depresses the ventilatory 
response  to  hypoxia.   Respiratory  reflexes  are  depressed  with  Propofol  making  the 
tracheal intubation and insertion of LARYNGEAL MASK AIRWAY easier than with 
thiopentone.
Cardiovascular System
The prominent effect of Propofol is a decrease in arterial blood pressure during 
induction of  anaesthesia.   The decrease in  arterial  blood pressure  is  associated  with 
decrease in cardiac output and stroke volume and systemic vascular resistance.  The 
decrease  in  systemic  pressure  following induction  is  due  to  both  vasodilatation  and 
myocardial depression.  The heart rate does not change significantly after the induction 
dose of propofol.  It is suggested that propofol either resets or inhibits the baroreflex. 
Propofol should be cautiously administered to patients with limited cardiac reserve or 
hypovolemia in whom a fall in peripheral vascular resistance or cardiac output might be 
disadvantageous.
Hepatic and Renal Function
Propofol  does  not  adversely  affect  hepatic  or  renal  function  as  reflected  by 
measurement  of  liver  transaminase  enzymes  or  creatinine  concentration.   Prolonged 
intravenous infusion of propofol may result in excretion of green urine reflecting the 
presence of phenols in urine.
Coagulation
Propofol does not alter tests of coagulation or platelet function.
Site of Injection
Pain on injection of propofol occurs in fewer than 10% of patients, when it is 
given into a large arm vein than into a small dorsal vein.
Other Effects
Propofol  does  not  block  the  secretion  of  cortisol  following  single  dose  or  a 
continuous  infusion.   Excitatory  responses  such  as  hypertonus,  tremor,  hiccough  or 
spontaneous  movement’s  may  be  seen.   Propofol  does  not  trigger  malignant 
hyperthermia.  Propofol reduce IOP markedly more than thiopentone on induction.  The 
vehicle for Propofol does not contain antibacterial preservative, hence strict asepsis to be 
maintained when handling the drug.
 Dosage and Administration
1. Induction of General anaesthesia
1.0– 2.5 mg/kg, reduced in patients over 55 years of age.
2. Maintenance  of  General  anaesthesia  80  -150  microgram/kg/min  IV  combined 
with N2O or an opiate and reduced in the patients over 50.
3. Sedation 10 - 50 microgram/kg/min IV.
Indications
1. Induction & maintenance of general anaesthesia.
2. For sedation during surgery
3. For outpatient anaesthesia
4. For sedation in ICU 
5. To treat nausea in post –operative period or following chemotherapy.
6. To relieve cholestatic pruritus as well as pruritus induced by spinal opiates.
FENTANYL 
Fentanyl is a phenyl piperidine derivative, synthetic opioid agonist that is structurally 
related to meperidine. As an analgesic fentanyl is  75 to 125 times more potent than 
morphine.
PHARMACODYNAMICS: 
A single dose of fentanyl administered intravenously has a more rapid onset and 
shorter  duration  of  action  than  morphine.  The  effect-  site  equilibration  time  is  6.4 
minutes. Rapid onset is due to its high lipophilicity and shorter duration of action is due 
to its rapid redistribution to inactive sites such as fat and skeletal muscles. It is estimated 
that  75% of  initial  fentanyl  dose  is  undergoing  first-pass  pulmonary  uptake.  When 
fentanyl is administered in continuous infusion, progressive saturation of these inactive 
tissue sites occur. As a result, the plasma concentration of fentanyl does not decrease 
rapidly.  So  the  duration  of  analgesia,  as  well  as  depression  of  ventilation,  may  be 
prolonged.
PHARMACOKINETICS:
Fentanyl  is  extensively  metabolized  by  N  –  demethylation,  producing  nor 
fentanyl, which is structurally similar to normeperidine. Nor fentanyl is excreted by the 
kidneys and can be detected in the urine for 72 hours after a single intravenous dose of 
fentanyl. Even though fentanyl has a short duration of action, its elimination half life is 
longer than that for morphine. This in infact due to a larger volume of distribution of 
fentanyl.  The larger volume of distribution is due to its greater lipid solubility and then 
more rapid passage of drug into tissues compared with less lipophilic morphine. The 
plasma concentrations of fentanyl are maintained by slow reuptake from inactive tissue 
sites, which account for its persistent effect.
CONTEXT SENSITIVE HALF TIME:
As the duration of continuous infusion of fentanyl increases beyond about 2 hours, 
the  context  sensitive  half-time  of  this  opioid  becomes  greater  than  sufentanil.  This 
reflects the saturation of inactive tissue sites with fentanyl during prolonged infusions 
and  return  of  the  opioid  from  peripheral  compartments  to  the  plasma.  This  tissue 
reservoir of fentanyl replaces the fentanyl eliminated by hepatic metabolism so as to 
slow the rate of decrease in the plasma concentration of fentanyl when the infusion is 
stopped.
DURING CARDIO PULMONARY BYPASS:
 All opioids show a decrease in plasma concentration with the initiation of cardio 
pulmonary  bypass.  The  degree  of  this  decrease  is  greater  with  fentanyl  because  a 
significant proportion of the drug adheres to the surface of the cardiopulmonary bypass 
circuit.  Sufentanil  and  alfentanil  may  provide  a  stable  plasma  concentration  during 
cardio pulmonary bypass. Elimination of fentanyl and alfentanil are prolonged by cardio 
pulmonary bypass.
CLINICAL USES:
Low dose of fentanyl, 1- 2mcg / kg, is injected to provide analgesia. Moderate 
dose of fentanyl, 2 – 20mcg/kg, is administered as an adjuvant to inhaled anesthetics to 
blunt the circulatory responses to (a) direct laryngoscopic intubation (b) sudden change 
in the level  of surgical  stimulation. Timing of fentanyl  administration to blunt  these 
responses should consider the effect-site equilibration time.
Larger  doses  of  fentanyl,  50  –  150mcg/kg  have  been  used  alone  to  produce 
surgical anaesthesia. The advantage of larger and sole fentanyl administration are (a) 
lack of myocardial depressant effect, (b) absence of histamine release, (c) suppression of 
the stress responses to surgery. Disadvantages include (a) post operative depression of 
ventilation and (b) possible patient awareness.
Fentanyl may be administered as a oral transmucosal preparation in a delivery 
device designed to deliver 5 – 20mcg / kg of fentanyl. In children aged 2 to 8 years, the 
preoperative administration of transmucosal fentanyl 15-20mcg/.kg 45 minutes before 
the  induction  of  anaesthesia,  reliably  induces  preoperative  sedation  and  facilitates 
induction of inhalation anaesthesia. But there is more chance of post operative nausea 
and vomiting in these patients. 
Transdermal fentanyl preparation delivering 75 to 100 mcg /hour result in peak 
plasma fentanyl concentrations for about 18 hours that tend to remain stable during the 
presence of the patch, followed by declining plasma concentration for several hours after 
removal  of  the  delivery  system,  reflecting  continued  absorption  from the  cutaneous 
depot. 
SIDE EFFECTS:
RESPIRATORY EFFECTS:
Persistent  or  recurrent  depression  of  ventilation  is  a  potential  post  operative 
problem.  There  are  two  theories  for  secondary  peaks  in  plasma  concentration  of 
fentanyl. One is due to sequestration of fentanyl in acidic gastric fluid. This sequestered 
fentanyl could then be absorbed from the more alkaline small intestine back into the 
circulation  to  increase  the  plasma  concentration  of  opioid  and  cause  depression  of 
ventilation to recur. Second is due to washout of opioid from the lungs as ventilation 
perfusion relationships are reestablished in the postoperative period. 
CARDIOVASCULAR EFFECTS:
Carotid  baroreceptor  reflex  control  of  heart  rate  is  markedly  depressed  by 
fentanyl.  Bradycardia  is  more  prominent  with  fentanyl  and  may  lead  to  occasional 
decreases in blood pressure and cardiac output. 
CENTRAL NERVOUS SYSTEM EFFECT:
Seizure activity has been described to follow rapid intravenous administration of 
fentanyl, sufentanil and alfentanil. In the absence of EEG, it is difficult to distinguish 
opioid –induced skeletal muscle rigidity or myoclonus from seizure activity. Opioids 
may produce a form of myoclonus secondary to depression of inhibitory neurons that 
could produce a clinical picture of seizure activity in the absence of EEG changes. 
Administration  of  fentanyl  and  sufentanil  to  head  injury  patients  has  been 
associated  with  modest  increase  in  intracranial  pressure  despite  maintenance  of  an 
unchanged PaCO2. These increases in intracranial pressure are typically accompanied by 
decrease in mean arterial pressure and cerebral perfusion pressure. 
DRUG INTERACTIONS:
Analgesic concentration of fentanyl greatly potentiates the effects of midazolam 
and  decreases  the  dose  requirements  of  propofol.  The  opioid  –  benzodiazepine 
combination  displays  marked  synergism with  respect  to  hypnosis  and  depression  of 
ventilation. 
        MIDAZOLAM
Midazolam  is  an  imidobenzodiazepine,  water  soluble  benzodiazepine. 
Benzodiazepines were introduced in early 1960s. Diazepam, the most popular drug of 
this group for the past 2 decades, is water insoluble, has a prolonged effect and is painful 
during  injection.  The  unique  chemical  structure  of  midazolam confers  a  number  of 
physiochemical properties that distinguish it from other benzodiazepines. This drug was 
synthesized in 1976 by Tryer and walser. 
CHEMISTRY:
 Benzodiazepines are so called because they consist of a benzene ring fused with a 
seven member diazepine ring. Various modifications in the structure of the ring systems 
have yielded compounds with similar activities. 
Midazolam with molecular weight of 362, has a fused imidazole that is different 
from classic benzodiazepines. The imidazole ring accounts for the basicity, stability of 
an aqueous solution  and rapid metabolism.  The ring exhibits  a  pH dependent  ring 
opening phenomenon. The ring opens at pH less than 4 making the drug soluble in 
aqueous solution. Once midazolam enters the body, the pH changes to 7.4 and drug 
assumes closed ring structure and becomes highly lipid soluble. Midazolam is the most 
lipid soluble benzodiazepine. 
PHARMACOKINETICS:
Midazolam is rapidly absorbed from gastro intestinal tract, but only 50% of the 
orally given drug enters the circulation, as substantial portion is metabolized during the 
first hepatic flow. Thus the oral dose is twice as high as intravenous dose.
Peak plasma concentrations are seen within an hour of ingestion.  When given 
intramuscularly,  the  absorption  is  more  predictable  than  diazepam.  Being highly  fat 
soluble it crosses blood brain barrier more easily than diazepam, to gain access to the 
receptors.  It  has  a  more  rapid  most  of  action.  After  intravenous  administration  of 
midazolam to healthy adults the disappearance of midazolam from the plasma proceeds 
in two distinct phases. The initial phase of rapid disappearance is due to principally to 
distribution  of  the  drug  while  the  final  and  slower  phases  of  disappearance  are 
attributable mainly  to biotransformation.  Midazolam volume of  distribution averages 
between 1 and 2.5 l/kg. Midazolam is tightly bound to plasma protein. After distribution 
equilibrium is  reached elimination  half-life  varies  from 1  to  4  hours.  Midazolam is 
metabolized  mainly  by  hepatic  microsomal  oxidative  mechanism,  by  a  process  of 
hydroxylation.  The  fused  imidazole  ring  is  oxidized  very  rapidly  to  both  1  and  4 
hydroxy  midazolam.  Both  these  products  are  conjugated  to  glucuronides  and  are 
excreted in the urine. The Metabolites have less than 1% activity of the parent drug. 
FACTORS AFFECTING PHARMACOKINETICS:
1. Old age – Elimination half-life is increased and clearance is delayed. 
2. Obesity – The Volume of distribution is increased. This increases the elimination 
half-life, but there is no change in the total metabolic clearance. 
3. Renal  insufficiency  –  As  less  than  1%  of  midazolam is  cleared  through  the 
kidney,  there  is  minimal  alternation  of  its  clearance  in  patients  with  renal 
insufficiency. The free fraction of midazolam in the plasma is increased due to 
decreased plasma binding. 
4. Pregnancy  –  Midazolam  crosses  the  placental  barrier,  but  the  placental 
transmission as  judged by fetal  – maternal  plasma ratio in animals  is  less  for 
midazolam than for diazepam. 
5. Gender – males are more susceptible to midazolam than female patients.  
MECHANISM AND SITE OF ACTION:
An important inhibitory neurotransmitter in the brain is gamma amino butyric acid 
(GABA), while glycine is the major inhibitory neurotransmitter in the spinal cord and 
brainstem. The benzodiazepines augment GABA thus producing sedation and 
anticonvulsant activity, while anxiolysis and muscle relaxation appear to be due to 
glycine mimetic effects in the spinal cord and brainstem.
Among the benzodiazepines midazolam has the greatest affinity for the receptors, 
but dissociate faster from the receptor, thus accounting for the rapid onset and shorter 
duration of action. Given intrathecally or epidurally, midazolam produces analgesia 
which is GABA mediated muscle relaxation produced by midazolam is due to 
potentiation of glycine action on the anterior horn cells. 
PHARMACODYNAMICS:
CENTRAL NERVOUS SYSTEM: 
Midazolam has anxiolytic, hypnotic, anticonvulsant, muscle relaxant and 
anterograde amnestic properties. It decreases the cerebral metabolic rate and cerebral 
blood flow. Cerebral perfusion pressure decrease as the systemic pressure falls more 
than the intracranial pressure. Given in doses of 0.25mg/kg it does not alter intracranial 
tension and therefore it can be used for neurosurgical procedures. Emergence from 
induction is more rapid than diazepam, but not so, when compared with thiopentone. 
Midazolam decreases the anesthetic requirement of inhalational agents.
CARDIOVASCULAR SYSTEM: 
Midazolam decreases the myocardial contractility and systemic vascular 
resistance and causes vasodilatation, thus causing fall in arterial pressure. The fall in 
blood pressure is similar to that caused by hypnotic doses of thiopentone, greater than 
that caused by equipotent doses of diazepam and less than that caused by propofol. It 
increases the heart rate. Midazolam does not abolish the stress response to intubation, 
but the increase in heart rate and blood pressure are less than seen with diazepam. 
Midazolam does not alter coronary vascular resistance and does not cause coronary steal 
phenomenon.
RESPIRATORY SYSTEM: 
Midazolam causes dose dependent depression of ventilation. In doses used for 
premedication or sedation, it does not alter the carbon dioxide response, but in doses 
above 0.2mg/kg it causes respiratory depression,  Apnea produced by midazolam is dose 
related and is more common in patients premeditated with opioids, in chronic 
obstructive pulmonary disorder patients, and following faster injection of the drug, 
Their respiratory depression is reversed by flumazenil but not by naloxone. 
INTRATHECAL MIDAZOLAM:
 
Spinal midazolam produces analgesia by binding to specific benzodiazepine 
receptors in the dorsal horn of the spinal cord. Muscle relaxation is by potentiating the 
effect of glycine which is an inhibitory neurotransmitter to the anterior horn cells.   
IN VITRO CHANGES IN TRANSPARENCY AND pH OF CSF CAUSED BY 
ADDING MIDAZOLAM:
CSF pH was decreased below 7.0 by adding more than 3mg of midazolam. CSF 
transparency was decreased by adding more than 7mg of midazolam. Midazolam in 
saline neither decreased the pH nor reduced the transparency. The pharmacokinetics of 
intrathecal midazolam depends on the molecular weight, lipid solubility and the 
systemic vascular absorption. 
ANTAGONIST OF MIDAZOLAM:
Flumazenil is an imidazo benzodiazepine, with specific benzodiazepine antagonist 
activity. Flumazenil binds with high affinity to specific sites when it competitively 
antagonizes the binding and allosteric effects of benzodiazepine. The intravenous 
administration of 0.3 to 1mg of flumazenil is usually sufficient to abolish the effects of 
therapeutic doses of benzodiazepines within 1to2 minutes. Additional doses may be 
required after 1 to 2 hours. 
USES OF MIDAZOLAM:
1. Premedication dose is 0.05 mg/kg to 0.1 mg/kg intramuscularly or 10-15 mg per 
oral. It has predictable absorption after intramuscular injection. It produces 
amnesia, anxiolysis and sedation. 
2. Intravenous sedation dose is 0.05 mg/kg to 0.1mg/kg .Sedation occurs without 
loss of airway reflexes, causes no vomiting and post operative drowsiness is less.
3. Induction dose is 0.15mg/kg to 0.3mg/kg and induction is faster than with 
diazepam.
4. DAY CARE SURGERY: Because of rapid onset and brief half-life midazolam is 
a suitable drug. But patients should not drive vehicles for at least eight hours as 
midazolam affects psychomotor function and postoperative instructions should be 
written down.
      5.   Midazolam can be used as treatment of emergence phenomenon 
DRUG INTERACTIONS:  
Erythromycin, clarithromycin and flucanozole increase the effect of midazolam 
due to inhibition of cytochrome P450 III A enzyme. H2 receptor antagonist also inhibit 
cytochrome P450 III A enzyme. Aspirin and probenecid increase the effect by 
competing for protein binding site. Phenytion, rifampicin and xanthines decrease the 
efficacy of midazolam due to increased metabolism by inducing cytochrome P 450. 
SIDE EFFECTS: 
Nausea and vomiting are minimal. Incidence of hiccough is 5.6%, cough is 1.5%.
                                       
 MATERIALS AND METHODS
This is a prospective, randomized study conducted in Government Rajaji Hospital, 
attached to Madurai Medical College.
After approval by the ethics committee -60  ASA grade 1 children belonging to both 
sexes, aged between 3 years and 12 years weighing between 10 and 30 kg scheduled for 
elective lower abdominal  general surgical procedures were entered in this study. 
Patients with history of asthma, morbid obesity, difficult intubation score were excluded 
fron the study. The selected children were randomized into two groups, group 1 and 
group2 by sealed envelope technique. All children received Injection atropine in the 
dose 0f 20mcg/kg intramuscularly 45 minutes before induction.
On arrival in the operation theatre room, continuous recording of oxygen saturation and 
pulse by pulse oximeter was done. Intravenous access was established. Blood pressure 
was recorded manually.
After recording the base line values, patients were preoxygenated with 100% oxygen for 
3 minutes. Injection midazolam in the dose of 0.05 mg/kg was given intravenously.
GROUP -1:
These children received Injection fentanyl 1mcg/kg IV, one minute later Injection 
propofol 2.5 mg/kg IV as an induction agent.
GROUP – 2:
These children received Injection fentanyl 2mcg/kg IV, one minute later followed by 
Injection propofol 2.5 mg/kg IV as an induction agent.
After 90 seconds of giving Injection propofol, LMA of appropriate size (2-wt.10-20 kg, 
2.5 –wt.20-30 kg) was inserted by theatre anesthetist who was unaware of the doses of 
drugs given. The LMA was inserted by standard partial inflation technique. The person 
who inserts the LMA will assess the ease of LMA insertion.
Any adverse response like 
                                      Inadequate jaw relaxation
                                      Gagging
                                      Coughing
                                      Limb or head movement
                                      Hiccoughs or laryngospasm were noted.
The response was graded in the following way
 MILD If the reaction was transient and minimal
 MODERATE If the reaction lasted for more than a few 
seconds but resolved within 20 seconds
 SEVERE If the reaction was sustained for more than 
2o seconds or needed additional induction 
agent to allow insertion
The overall ease of insertion of LMA was graded as excellent, satisfactory or poor.
EXCELLENT Absence of any adverse response
SATISFACTORY Mild or moderate response not affecting 
the LMA insertion
POOR Severe response affecting the LMA 
insertion or requiring additional induction 
dose
If additional doses were required Injection propofol in the dose of 0.5 mg/kg was given 
in incremental doses.
After inserting the LMA, the cuff was inflated with the prescribed volume of air (10 ml 
-2 size, upto 14 ml -2.5 size).Size 2 and 2.5 were used in the study. After confirming 
bilateral air entry, the LMA was secured with adhesive plasters.Anaesthesia was 
controlled by using non depolarizing muscle relaxant Injection atracurium 0.5 mg/kg IV 
and maintained with oxygen nitrous oxide 50 % each.
Parameters observed were
1. Number of attempts in inserting the LMA.
2. Overall ease of LMA insertion.
3. Pulse rate.
4. Blood pressure both systolic and diastolic, from this mean arterial pressure is 
calculated.
Pulse rate and blood pressure were noted before LMA insertion, at 1 minute and at 5 
minutes.
Any movement of the patient and application of the surgical draping was avoided upto 5 
minutes after inserting LMA.The study ends 5 minutes after inserting the LMA.
STATISTICAL METHOD
Results were expressed on mean ± standard deviation. Statistical significance was 
determined by student’s  t  test.
                             OBSERVATION AND RESULTS
The demographic data of the patients included in this study are shown in the following 
TABLE - 1. 
Group
No. of. cases
males                     females
age weight
1 27 3 6.7 ± 3.1 18.7 ± 5.8
2 28 2 6.5 ± 3.1 17.3 ± 5.2
There was no significant difference between both the groups in terms of age and weight 
( p value 0.869 for age, p value 0.319 for weight).
TABLE -2: PERCENTAGE OF LMA INSERTION 
Group n
Successful 
insertion in 1st 
attempt
Insertion after 
additional bolus 
dose
1 30 20 10
2 30 28 23
Table -2 shows the number of LMA insertions in first attempt and after additional bolus 
doses in both the groups.
Applying paired t – test showed a p value of 0.042 (< 0.05) which is statistically 
significant.
TABLE – 3 Shows the overall ease of insertion of LMA in both the groups.
 In group 1 excellent conditions of insertion were noted in 50 % of cases(15)while in 
group 2 excellent conditions occurred in 86.6 % of cases (26 )P value of 0.008 ( < 0.05 ) 
which is statistically significant.
The conditions for LMA insertion was poor in 33.3 % of cases (10) in group 1 and 6.6 % 
of cases in group 2, which is also very significant.
TABLE –4 shows the 
comparison between Groups 1 and 2 of pulse rate base line value, before LMA insertion, 
at 1 minute and at 5 minutes. .
There is significant difference in pulse rate between groups I & II before LMA insertion 
and at 1 & 5 minutes. (p value <0.05 )
EVENTS GROUP 1 GROUP 2
Base line 95.23 ±  7.42 95.73 ± 8.06
Before LMA insertion 86.53±6.12 83.13±7.11
At 1 minute 88.41±8.18 83.8 ±7.07
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At 5 minutes 85.93 ± 6.35 83.6 ± 6.77
TABLE 5 shows the comparison between groups 1 and 2 0f Mean arterial blood 
pressure the base line value, before LMA insertion, at 1 minute and at 5 minutes. 
EVENTS GROUP 1 GROUP2
Base line 77.5 ± 7.21 76.7 9± 3.72
Before LMA insertion 71.63 ± 7.05 66.99 ±4.30
At 1 minute 75.62 ± 8.25 70.59 ± 6.66
At 5 minutes 74.14 ±  5.66 70.90 ± 4.92
There is significant difference in mean arterial pressure between groups I & II before 
LMA insertion and at 1 & 5 minutes. (p value <0.05 )
DISCUSSION
The LMA has been a major advance in airway management. It has 
many advantages over the face mask or the endotracheal tube, but it 
is contraindicated in situations where the child is prone to aspirate 
gastric contents and when the lung compliance is poor.LMA 
insertion is easily learned and quickly accomplished without need for 
direct visualization of the airway.
The most common problems interfering with successful positioning of the LMA are 
1.Difficulty negotiating the posterior pharynx 
2. Inadequate depth of anaesthesia
3. Using the wrong sized LMA..
Successful LMA insertion requires adequate depression of upper airway reflexes which 
accompanies general anaesthesia.Coughing, gagging and limb movement can occur if 
LMA insertion is attempted in an inadequate plane or the dose of drugs given are not 
sufficient enough to suppress the airway reflexes. Therefore it is prudent to select the 
dosage of drugs in such a way to suppress airway reflexes for easy insertion of LMA and 
also to avoid the harmful side effects of the drug.
.Propofol is used for insertion of LMA as it has a depressant effect on airway reflexes. 
As propofol itself possesses no analgesic activity, additional analgesics are frequently 
administered during total i.v. anaesthesia with propofol. There are some reports that 
fentanyl and alfentanil reduce the 50% or median effective concentration (EC50) of 
propofol used for various noxious stimuli.
.M Kodaka et al ( BJA 2004 ) did  a study to determine the effective concentration for 
50% of the attempts to secure laryngeal mask insertion (predicted EC50LMA) of 
propofol using a  target-controlled infusion (DiprifusorTM) and investigated whether 
fentanyl influenced these required concentrations, respiratory rate (RR) and bi-spectral 
index (BIS) .They concluded that a fentanyl dose of 0.5 µg kg–1 is sufficient to decrease 
predicted EC50LMA with minimum respiratory depression and without a high BIS 
value. The results of their study was that the predicted EC50LMA of the control, 
fentanyl 0.5, 1 and 2 µg kg–1 groups were 3.25 (0.20), 2.06 (0.55), 1.69 (0.38) and 1.50 
(0.54) µg ml–1 respectively.
Martlew et al (BJA 1996) studied the effective doses of propofol for insertion of LMA 
in 50 unpremedicated children and in 60 children premedicated with midazolam (0.5 
mg/kg 30-60 minutes before anaesthesia).Propofol requirements in premedicated 
children were reduced by one-third. The doses required for satisfactory LMA insertion 
in 50% and 90% of unpremedicated children were3.8 mg/kg and 5.4 mg/kg respectively; 
those for premedictated children were 2.6 mg/kg and 3.6 mg/kg respectively.
As propofol is known to produce cardio respiratory depression in children at doses 
nearing 5 mg/kg, hypotension and prolonged apnea may be a problem
Short et al (BJA 1991) has shown that propofol and midazolam act synergistically in 
combination..
In our study we have compared the effectiveness of two doses of fentanyl 1mcg/kg and 
2mcg/kg along with a standard dose of propofol (2.5 mg/kg) and midazolam 
(0.05mg/kg).
Midazolam is given intravenously once IV access is established, followed slowly by 
fentanyl 1mcg/kg or 2mcg/kg according to the study group to which they are placed. 
Sufficient time of three minutes is given for the peak effect of fentanyl and midazolam 
to take over. Then Inj. Propofol in a precalculated dose of 2.5 mg/kg is given along with 
Inj lidocaine to alleviate the pain of propofol injection. It is preferable to give propofol 
in a running drip to ensure stable levels in blood. Then mask ventilation is continued for 
90 seconds for the peak action of propofol to occur, to achieve adequate anesthetic depth 
for insertion of LMA.
Successful insertion at first attempt
The adequate anesthetic depth provided by GROUP 2 agents –fentanyl 2mcg/kg 
(propofol 2.5mg/kg and midazolam 0.05 mg/kg) facilitated easy insertion of LMA with 
least adverse responses. High success rates in first attempt were obtained in 93.3 % of 
patients. All insertion attempts were done by the classical method with the cuff partially 
inflated as studies have shown a high success rate with this technique.
Although both methods of insertion (the classical and the partially inflated technique) 
were satisfactory, partial inflation of the LMA improved the ease of insertion in children 
as assessed by time to insertion and success rate on the first attempt. Inflation of the cuff 
of the smaller sized LMAs after insertion often displaces the LMA and alters its position 
while the inflated LMA tends to insert to the proper depth and requires no further 
adjustment.
Pankaj Kundra et al conducted a study in 62 ASA 1 and 2 children who were randomly 
allocated for the evaluation of LMA insertion by the midline approach with the cuff 
completely deflated or laterally with the cuff partially inflated. Propofol was used as the 
sole induction agent in all children.  They assessed the ease of insertion, position of the 
LMA with fibreoptic laryngoscope and incidence of stomach insufflation. They noted 
fewer attempts and a significant reduction in the time for insertion in group with LMA 
insertion attempted laterally with cuff partially inflated.
Patients’ response to LMA insertion
The adverse response to LMA insertion like coughing ,gagging ,head and limb 
movement were considerably low in GROUP 2 which received fentanyl in a dose of 
2mcg/ kg. This is due to effective attenuation of airway reflexes by this dose. This dose 
of fentanyl is also very safe as it resulted in no respiratory depression in the immediate 
post operative period and good awakening at the end of the surgery. Only 6.6% of the 
patients had severe adverse response to LMA insertion in GROUP2.
Overall ease of insertion of LMA
Excellent insertion conditions with minimal adverse reactions were seen in the GROUP 
2 which received fentanyl in dose of 2mcg/kg.Excellent conditions occurred in 86.6% in 
GROUP2 .Only 50 % of patients in GROUP1 (fentanyl 1mcg/kg ) had excellent 
insertion conditions.
Hemodynamic parameters
Both the groups showed marked decrease in pulse rate and mean arterial pressure due to 
the synergistic action of the drugs on the hemodynamics. There was no marked rise in 
pulse or mean arterial pressure even after insertion of LMA in group 2 denoting the 
adequate depth of anaesthesia provided by the drugs. There was no marked fall in blood 
pressure necessitating the use of vasopressors or leading to cessation of drug 
administration. Thus the hemodynamic effects were clinically insignificant, much less 
than with tracheal intubation, comparable to the response recorded with the insertion of 
an oropharyngeal airway. This correlates with the study conducted by Mason, Bingam et 
al (Anaesthesia1990).
Safety concern in pediatrics
 Mason et al used LMA in 200 children during a variety of surgical procedures. A clear 
airway was ultimately achieved in 191 children. They concluded that the size 2 laryngeal 
mask airway can be successfully used within the weight range 6-30 kg.
Brimacombe J et al (Anaesthesia1996) studied LMA use in 1400 children. They 
conclude that the laryngeal mask provides a safe and effective form of airway 
management for infants and children in the hands of supervised anaesthesia trainees both 
for spontaneous and controlled ventilation using either isoflurane or total intravenous 
anaesthesia.
O’ Neil et al (Anaesth.  Analg. 1994)   concluded that the use of the laryngeal mask 
airway (LMA) permits the maintenance of a patent airway with successful insertion rates 
of the LMA on the first attempt varying between 67%–92% in children.
                                 
     SUMMARY AND CONCLUSION
The laryngeal mask airway has been a major advance in airway management. The 
LMA  was  designed  primarily  as  a  means  of  offering  some  of  the  advantages  of 
endotracheal intubation while avoiding a fundamental disadvantage of visualization of 
the vocal cords and forcing them apart. The increasing emphasis on day care anaesthesia 
has led to greater use of laryngeal mask airway, as an alternative to face mask and in 
some cases conventional tracheal intubation.LMA insertion is easily learned and quickly 
accomplished.  It  minimally  interferes  with  the  cardiovascular  system  and  avoids 
stimulation of the trachea in patients where this is undesirable.
The aim of this study was to assess the ease of insertion comparing two different doses 
of  fentanyl  (similar  dose  of  Propofol  &  midazolam in  both  groups)  in  60  children 
premedictated with Inj.atropine 20mcg /kg undergoing elective surgery requiring LMA 
insertion.  They  were  randomly  allocated  by  closed  envelope  technique  to  receive 
propofol  2.5mg/kg  midazolam  0.05  mg/kg  Inj.fentanyl  1  mcg/kg  (GROUP  1)  or 
Inj.fentanyl  2mcg/kg  (GROUP  2).  90  seconds  after  induction  LMA  insertion  was 
attempted and graded. The adverse responses and vital parameters like heart rate mean 
arterial pressure were measured before induction of anaesthesia and upto 5 minutes after 
LMA insertion.
Of the two groups compared, Group II receiving fentanyl 2 mcg/kg (with propofol 2.5 
mg/kg and midazolam 0.05mg/kg) had excellent conditions for LMA insertion with no 
adverse  responses  in  86.6  %  of  patients.  The  decrease  in  heart  rate,  mean  arterial 
pressure after insertion when compared with the baseline was statistically significant. 
There were minimal adverse effects in 6.6 % of patients. The insertion was successful in 
first attempt in 93.3 % of patients.
 
Group I patients receiving fentanyl 1 mcg/kg (with propofol 2.5 mg/kg and midazolam 
0.05mg/kg) had excellent conditions in only 50 % of patients. The incidence of adverse 
responses was high in this group 33.3 % as compared to 6.6 % in group II, indicating 
inadequate depth of anaesthesia in this group I. The success of insertion in first attempt 
in this group was low (66.6 %). 
To conclude, induction of anaesthesia with fentanyl 2mcg/kg, propofol 2.5 mg/kg and 
midazolam 0.05mg/kg provides excellent conditions for laryngeal mask insertion with 
high  success  rate  of  insertion  in  first  attempt.  It  is  also  associated  with  least 
hemodynamic changes and adverse responses. Induction with fentanyl 1 mcg/kg with 
propofol 2.5 mg/kg and midazolam 0.05mg/kg provides less satisfactory conditions for 
laryngeal mask insertion with more adverse responses and considerable hemodynamic 
changes.
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